RE:Smoking Gun? Valeant Pharmaceuticals International (NYSE:VRX) Rating
Analysts at UBS Securities have $255.00 PT on Valeant Pharmaceuticals International (NYSE:VRX). UBS Securities’s PT means a potential upside of 159.01% from the company’s last stock close price. The rating was revealed in an analyst note on Friday morning.
Out of 17 analysts covering Valeant Pharmaceuticals Intl (NYSE:VRX), 12 rate it “Buy”, 0 “Sell”, while 5 “Hold”. This means 71% are positive. $310 is the highest target while $135 is the lowest. The $236.73 average target is 152.35% above today’s ($93.81) stock price. Valeant Pharmaceuticals Intl was the topic in 29 analyst reports since July 21, 2015 according to StockzIntelligence Inc. UBS maintained the stock on October 30 with “Buy” rating. Scotia Capital maintained it with “Sector Outperform” rating and $250 target price in an October 20 report. Mizuho upgraded the shares of VRX in a report on October 27 to “Buy” rating. Bank of America maintained the firm’s rating on September 30. Bank of America has “Buy” rating and $290 price target. Finally, Deutsche Bank maintained the stock with “Hold” rating in an October 20 report.